Clinical Challenges

Heart Failure in a Breast Cancer Survivor

Susan Moore

breast neoplasms, survivors
ONF 2012, 39(2), 147-150. DOI: 10.1188/12.ONF.147-150

A 64-year-old woman named J.G. was diagnosed with a right side, node-negative, HER2-positive, hormone-negative (stage I) breast cancer about eight years ago. Following lumpectomy and sentinel node biopsy, she was referred to a medical oncologist at a National Cancer Institute-designated comprehensive cancer center for consultation on the need for adjuvant chemotherapy. The oncologist recommended four cycles of doxorubicin plus cyclophosphamide. Final trials for trastuzumab in the adjuvant setting had not been completed at the time of the consultation. And, because of the small size of the primary tumor (0.8 cm), the oncologist did not recommend trastuzumab, citing evolving concerns about cardiotoxicity related to long-term use of the drug. J.G. had a positive family history of cardiac events: Both of her parents died from sudden myocardial infarctions in their 60s and her older brother had congestive heart failure (CHF). J.G. had a personal history of hypertension (for which she declined antihypertensive treatment), was obese (body mass index of 38.4), and was sedentary. She agreed with the treatment plan as discussed with her oncologist. A prechemotherapy cardiac assessment of an electrocardiogram and multigated acquisition (MUGA) scan showed no cardiac problems. The MUGA scan's result for left ventricular ejection fraction (LVEF) was 61% (normal is 50% or greater). J.G. proceeded with treatment, which she tolerated well. Following chemotherapy, she underwent six weeks of external beam radiation to her right breast with a boost to the tumor site.

Jump to a section

    References

    American Heart Association. (2011). Heart disease and stroke statistics: 2011 Update. Circulation, 123, E18-E209.
    Hershman, D. L., & Shao, T. (2009). Anthracycline cardiotoxicity after breast cancer treatment. Oncology, 23, 227-234.
    Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., … Yancy, C. W. (2009). 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology, 53(15), E1-E90.
    Nadeem, O., Rauwerdink, C., Beggs, V. L., Parr, D. D., Kono, A. T., & Schwartz, G. N. (2011). Incidence of anthracycline-induced cardiotoxicity in patients with breast cancer: A single center's experience [Abstract]. Retrieved from http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=84124
    Russell, S. D., Blackwell, K. L., Lawrence, J., Pippen, J. E., Roe, M. T., Wood, F., … Mahaffey, K. W. (2010). Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by tras-tuzumab adjuvant therapy. Journal of Clinical Oncology, 28, 3416-3421.
    Criteria Committee of the New York Heart Association. (1994). Nomenclature and criteria for diagnosis of diseases of the heart and great vessels (9th ed.). Boston, MA: Little, Brown and Co.
    Hershman, D. L., & Shao, T. (2009). Anthracycline cardiotoxicity after breast cancer treatment. Oncology, 23, 227-234.
    Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., … Yancy, C. W. (2009). 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults. Journal of the American College of Cardiology, 53(15), E1-E90.
    McKee, P. A., Castelli, W. P., McNamara, P. M., & Kannel, W. B. (1971). The natural history of congestive heart failure: The Framingham study. New England Journal of Medicine, 285, 1441-1446.
    Moore, S. (2009). Prechemotherapy cardiac assessment. Oncology Nursing Forum, 36, 503-506. doi:10.1188/09.ONF.503-506
    Viale, P. H., & Yamomoto, D. S. (2008). Cardiovascular toxicity associated with cancer treatment. Clinical Journal of Oncology Nursing, 12, 627-638. doi:10.1188/08.CJON.627-638